Chia‐Chang Wu

Taipei Medical University-Shuang Ho Hospital

Papers

2

Total Citations

28

H-Index

2

About

Dr. Chia-Chang Wu is a leading urologic oncologist whose research focuses on optimizing surgical management for upper tract urothelial carcinoma (UTUC), a particularly prevalent malignancy in Taiwan. His major contributions center on comparing minimally invasive nephroureterectomy techniques—hand-assisted, laparoscopic, and robotic—to determine the safest and most effective approaches. His landmark 2021 study, with 24 citations, provided critical evidence on oncological outcomes and surgical complications from the Taiwan UTUC Collaboration Group, a large-scale national database he helped establish. More recently, his 2024 work on segmental ureterectomy outcomes offers vital guidance for organ-sparing surgery in a high-endemic region, addressing a gap in NCCN guideline applicability. Dr. Wu’s research is instrumental in shaping treatment protocols for UTUC, demonstrating that robotic and laparoscopic methods can achieve comparable oncological control while reducing surgical morbidity. His collaborative nationwide studies have made Taiwan a global reference point for UTUC management, directly impacting clinical decisions for thousands of patients. Through rigorous comparative effectiveness research, Dr. Wu continues to advance precision surgery in urologic oncology.

Research Focus

Key Achievements

2
H-Index
2
Papers
28
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Comparing Oncological Outcomes and Surgical Complications of Hand-Assisted, Laparoscopic and Robotic Nephroureterectomy for Upper Tract Urothelial Carcinoma
24 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 42
🏛 Institutions: Taipei Medical University-Shuang Ho Hospital

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago